Canurta Therapeutics

Develops multi-target botanical therapies using AI for inflammation and neurological diseases.

Website: https://www.canurta.com/

Cover Block

PUBLIC

Field Value
Name Canurta Therapeutics
Tagline Develops multi-target botanical therapies using AI for inflammation and neurological diseases
Headquarters Ontario, Canada
Founded 2021
Stage Seed
Business Model B2B
Industry Healthtech
Technology Biotech / Life Sciences
Geography North America
Growth Profile Venture Scale
Founding Team Solo Founder
Funding Label $10M+
Total Disclosed ~$13.22M (including $3.22M non-dilutive)

Links

PUBLIC

Executive Summary

PUBLIC

Canurta Therapeutics is an Ontario-based pre-clinical biotech building botanical drugs from rare hemp-derived polyphenols, with a lead candidate (CNR-401) targeting amyotrophic lateral sclerosis and an AI-assisted discovery platform called PolyKye sitting underneath the pipeline [Canurta]. The company is worth investor attention now because it has crossed two thresholds that most botanical drug developers never reach: a Pre-IND and Orphan Drug submission for its lead asset in February 2025 [Canurta, 2026], and a patent estate of more than 20 granted assets globally [Newsfile Corp, 2026]. Founded in 2021 by Akeem Gardner, a Brampton-born entrepreneur who previously co-founded health and wellness venture Atlas 365, Canurta grew out of a research relationship with University of Guelph scientists studying cannflavins A and B [Ontario Centre of Innovation]. The company has reportedly raised over $13 million in combined dilutive and non-dilutive capital, with the Accelerator Centre named as an institutional backer and Pre-Seed/Seed activity logged in 2021 [PitchBook] [Canurta]. The differentiation rests less on the AI layer (which is increasingly common) and more on the proprietary upstream supply chain: cGMP-verified, USDA Organic and Kosher certified extraction infrastructure via Canurta Naturals USA, and a recent operational transition into the FSOil facility in Woodburn, Oregon [Canurta]. Over the next 12 to 18 months, three milestones will determine whether the equity story holds: the start of CNR-401 clinical work in 2025, the contemplated TSXV listing [BioPharmIQ], and execution on early commercial programs in Brazil and Germany [Canurta, 2026]. The combination of a rare-disease orphan strategy, a defensible IP wall, and owned extraction capacity is uncommon at the seed stage, though the asset remains pre-clinical and the cap table is only partially disclosed in public databases.

Data Accuracy: GREEN -- Confirmed by Canurta investor materials, PitchBook, Crunchbase, and Newsfile Corp.

Taxonomy Snapshot

| Axis | Value | |---| | Stage | Seed | | Business Model | B2B | | Industry / Vertical | Healthtech / Biotech | | Technology Type | Biotech / Life Sciences (AI-assisted discovery) | | Geography | North America (Ontario HQ; Oregon operations) | | Growth Profile | Venture Scale | | Founding Team | Solo Founder | | Funding | $10M+ disclosed |

Company Overview

PUBLIC

Canurta Therapeutics began in 2021 as the biotech successor to founder Akeem Gardner's earlier hemp wellness venture, Atlas 365, after a research collaboration formed with University of Guelph scientists studying cannflavins and other rare polyphenols [Ontario Centre of Innovation] [PitchBook]. The company is headquartered in Ontario, with Gardner based in Brampton, and operates an extraction footprint in Woodburn, Oregon through its Canurta Naturals USA subsidiary [Crunchbase] [Canurta]. The original thesis, that hemp biomass and waste streams contain underexplored bioactives with anti-inflammatory and neuroprotective potential, has narrowed over time into a focused pre-clinical drug development pipeline rather than a nutraceutical brand play.

The milestone arc is short but legible. Founding and initial Seed activity occurred in 2021 [PitchBook]. By 2024 the company had built out a research and IP base and hosted FutureBotanica 2024, an industry convening on botanical drug development [Canurta]. In February 2025, Canurta filed Pre-IND and Orphan Drug applications for CNR-401 in ALS [Canurta, 2026], the most consequential regulatory step in the company's history to date. In the same period, Canurta Naturals announced an operational transition into the FSOil facility in Woodburn, Oregon, expanding North American botanical extraction capacity while retaining the existing operational team [Canurta] [FSOil]. The company has also been reported as preparing for a TSXV listing in 2025 [BioPharmIQ], though that path has not been confirmed by an exchange filing in the public record.

Gardner has been a visible spokesperson for the science: he presented at CannMed 2024 on May 14, 2024, the Life Sciences Investor Forum on November 14, 2024, and the SUNY Cannabis Conference on January 14, 2025 [LinkedIn, 2026] [GlobeNewswire, 2026] [Canurta, 2026]. The cumulative picture is a company that has graduated from a hemp-processing concept into a pre-clinical drug developer with regulatory filings, owned infrastructure, and a public-markets ambition.

Data Accuracy: GREEN -- Confirmed by Canurta primary materials, PitchBook, Crunchbase, and Ontario Centre of Innovation.

Product and Technology

MIXED

Canurta's product strategy splits into two layers: a pre-clinical drug pipeline led by CNR-401 [PUBLIC], and a discovery and manufacturing platform underneath it that the company brands as PolyKye [PUBLIC]. CNR-401 is positioned as a multi-target botanical therapy for amyotrophic lateral sclerosis, with Pre-IND and Orphan Drug applications submitted in February 2025 [Canurta, 2026] and trials referenced as entering in 2025 [Canurta]. Early commercial programs in Brazil and Germany are also referenced in the company's investor summary [Canurta, 2026]; the structure of those programs (compassionate use, named patient access, partnered distribution) is not specified in the public record.

The PolyKye platform is described by the company as an AI-assisted discovery engine that screens both known and novel chemical entities derived from hemp polyphenols, with synergy prediction used to optimize multi-compound combinations for anti-inflammatory and neuroprotective effect [Canurta]. The differentiation claim is less about the AI layer itself, which is increasingly commodity in early-stage drug discovery, and more about the upstream substrate: a botanical input library that the company has built proprietary chemistry around, supported by more than 20 granted global patents [Newsfile Corp, 2026]. Canurta also integrates blockchain-based traceability into its physical supply chain to meet FDA documentation requirements [Canurta]; whether that becomes a meaningful regulatory differentiator or a marketing feature is not yet testable from public data.

The manufacturing layer is the most under-discussed asset. Through Canurta Naturals USA, the company operates a cGMP third-party verified, USDA Organic and Kosher certified extraction facility [Canurta Naturals], and the Canurta Naturals operational transition into the FSOil facility in Woodburn, Oregon [PUBLIC] expands cGMP botanical extraction capacity in North America [Canurta]. Owning extraction infrastructure is unusual for a seed-stage drug developer and reduces dependence on contract manufacturers for supply of the active botanical input. The partnership with Applied Pharmaceutical Innovation and Dr. Neal M. Davies at the University of Alberta adds external GMP and formulation expertise on the drug development side [Applied Pharmaceutical Innovation], and expanded preclinical work with Washington State University and traction in C2MP round out the academic collaboration footprint [Canurta, 2026].

Data Accuracy: YELLOW -- Pipeline and platform claims are largely company-sourced; the regulatory filings and patent count are independently corroborated by Newsfile Corp.

Market Research and Opportunity

PUBLIC

The market case for Canurta sits at the intersection of three slow-moving but durable trends: the rising clinical and economic burden of neurodegenerative disease, the regulatory reopening to botanical drugs following FDA guidance updates, and the institutional appetite for orphan-designated assets with shorter and cheaper paths to approval.

ALS, the lead indication for CNR-401, is the immediate addressable market. ALS is a rare disease with limited approved therapies and high unmet need, which is precisely why the Orphan Drug pathway exists and why the FDA has historically been receptive to novel mechanisms in this category. Canurta has not published a third-party-sourced TAM figure, and the public record contains no named analyst report sizing the company's specific opportunity. Investors evaluating the asset will need to triangulate from the broader ALS therapeutics market and from comparable orphan neurology approvals rather than from a Canurta-supplied number. The adjacent inflammation market, which the PolyKye platform is also pointed at, is meaningfully larger but also meaningfully more crowded with incumbent biologics and small molecules.

The demand drivers the cited research surfaces are consistent. Industry coverage has framed Canurta's space as the convergence of botanical pharmacology and AI-assisted discovery [Canurta] [CanadianSME], with rising interest in multi-target therapies for diseases (such as ALS and chronic inflammation) where single-target approaches have repeatedly disappointed. The company's own thesis, that complex diseases respond better to synergistic multi-compound interventions than to single molecules, is gaining academic support but remains commercially unproven at the regulatory finish line. The substitute markets to watch are nutraceuticals (lower regulatory bar, lower margin, much faster cash) and conventional small-molecule neurology pipelines (higher cost, established reimbursement). Canurta has explicitly chosen the harder, slower drug-development route while retaining optionality on the extraction and ingredient side through Canurta Naturals.

Regulatory and macro forces cut both ways. The FDA's 2016 botanical drug guidance and subsequent approvals have established that botanical mixtures can reach approval, but the pathway remains uncommon and expensive. Orphan designation, if granted for CNR-401, would bring market exclusivity, tax credits, and waived user fees, materially improving the economics of a rare-disease asset. On the negative side, the company is pre-clinical, and the gap between Pre-IND filing and a readable clinical signal is the single largest value-determining variable in the next 24 months.

| Sizing claim | Value | Source | |---| | Total capital raised | Over $13M | [Newsfile Corp, 2026] | | Non-dilutive funding component | $3.22M | [Canurta] | | Granted global patents | 20+ | [Newsfile Corp, 2026] |

Analyst takeaway: the most defensible numbers in the public record are about Canurta's inputs (capital, IP, infrastructure) rather than its market. Until a third-party report sizes the ALS botanical opportunity or the company publishes peer-reviewed pre-clinical data, market sizing for this asset is best treated as comparable-driven rather than bottom-up.

Data Accuracy: YELLOW -- Capital and IP figures corroborated; market sizing not independently sourced.

Competitive Landscape

MIXED

Canurta sits in a thinly populated competitive segment: pre-clinical, AI-assisted, polyphenol-focused botanical drug developers pointed at neurology and inflammation.

The competitive map is best understood in three layers. The first layer is conventional ALS therapeutics developers, which include large pharmaceutical companies advancing small molecules and biologics through Phase 2 and 3, plus a handful of well-capitalized biotechs specifically targeting motor neuron disease. Canurta does not compete with these on capital or clinical maturity; it competes on mechanism, arguing that a synergistic multi-compound botanical can address pathways that single-target drugs have missed. The second layer is botanical drug developers more broadly, a small group operating under the FDA's 2016 botanical guidance, where the bottleneck is less science than regulatory craftsmanship and chemistry-manufacturing-controls discipline. The third layer is AI-driven drug discovery platforms, which is a crowded category but mostly oriented to synthetic small molecules rather than natural product mixtures. Canurta's PolyKye platform is positioned at the intersection of layers two and three, which is genuinely uncommon.

Where Canurta has a defensible edge today: owned cGMP extraction capacity through Canurta Naturals USA and the FSOil transition [Canurta], a 20-plus patent estate concentrated on rare polyphenols [Newsfile Corp, 2026], and academic relationships at University of Guelph, University of Alberta, and Washington State University that give it credible chemistry and pharmacology depth [Ontario Centre of Innovation] [Applied Pharmaceutical Innovation] [Canurta, 2026]. The durability of these edges is mixed. The IP wall is durable so long as claims survive prosecution and challenges. The manufacturing edge is durable but capital-intensive. The academic relationships are durable only as long as Canurta funds the work.

Where Canurta is most exposed: the company has not yet generated clinical efficacy data, which is the only currency that matters to a strategic acquirer or a Phase 2 partner. A larger ALS-focused biotech with a single Phase 2 readout in hand has access to capital, talent, and conviction that a pre-clinical botanical developer simply does not. Canurta also does not own a commercial channel into neurology prescribers, and the early commercial programs in Brazil and Germany are referenced in investor materials but not yet detailed in the public record [Canurta, 2026].

The most plausible 18-month competitive scenario: winner if Canurta secures Orphan Drug designation for CNR-401 and converts the Pre-IND into an open IND with a credible Phase 1 protocol, in which case the company becomes one of a very small number of botanical assets in active ALS clinical development and a logical partnering candidate; loser if the IND is delayed past 2026 and the contemplated TSXV listing prices into a soft small-cap biotech tape, compressing the equity story before clinical proof points arrive. Both outcomes hinge on regulatory cadence rather than competitive displacement.

Data Accuracy: YELLOW -- Competitive structure inferred from category knowledge; no named direct competitors in the public record.

Opportunity

PUBLIC

If Canurta executes on the regulatory and clinical milestones it has set up, the prize is the chance to become the first commercially successful AI-discovered botanical drug developer with owned extraction infrastructure, a category that today has no clear leader.

The headline opportunity. The single largest outcome Canurta could plausibly become is the default platform for botanical drug development in North America: a vertically integrated company that controls the cultivar, the extraction, the chemistry library, the AI-driven combination screening, and the clinical pipeline. The cited evidence makes this reachable rather than aspirational because the foundational pieces are already in place: a Pre-IND filing for a lead asset in a high-need rare disease [Canurta, 2026], a 20-plus patent estate [Newsfile Corp, 2026], cGMP extraction capacity [Canurta], and a first institutional capital base of more than $13 million [Newsfile Corp, 2026]. Most pre-clinical biotechs at the seed stage have one or two of these; having all four at once is the actual differentiator.

Growth scenarios.

| Scenario | What happens | Catalyst | Why it's plausible | |---| | Orphan ALS asset | CNR-401 secures Orphan Drug designation and progresses through Phase 1, becoming a partnering candidate for a larger neurology biotech | FDA Orphan grant on the February 2025 submission [Canurta, 2026] | The Orphan pathway is designed for exactly this profile of rare-disease asset with novel mechanism | | Platform licensing | PolyKye becomes a discovery-as-a-service platform licensed to pharma and nutraceutical partners, generating non-dilutive revenue while the in-house pipeline matures | Partnership announcements with named pharma; expansion of the API and University of Alberta collaboration model [Applied Pharmaceutical Innovation] | The company has already structured one academic-industrial partnership and operates owned manufacturing that can fulfill licensee supply needs | | Public-markets compounding | TSXV listing in 2025 gives Canurta a public currency to acquire complementary botanical IP and accelerate the pipeline | Successful TSXV listing [BioPharmIQ] followed by a clinical readout | Small-cap Canadian biotech has historically funded botanical and natural product developers when an orphan asset is in hand |

What compounding looks like. The flywheel is the interaction between the platform and the pipeline. Each new compound advanced through PolyKye expands the chemistry library, which improves the AI synergy predictions, which makes the next compound cheaper and faster to validate. Each granted patent strengthens the moat around the next discovery. Each cGMP batch run through Canurta Naturals lowers the marginal cost of supplying the next pre-clinical or clinical program. The early evidence that this flywheel is starting includes the patent count crossing 20 [Newsfile Corp, 2026], the operational expansion into FSOil [Canurta], and the academic partnership footprint with three named universities [Ontario Centre of Innovation] [Applied Pharmaceutical Innovation] [Canurta, 2026].

The size of the win. Public comparables for orphan neurology assets vary widely, but rare-disease biotechs with a single Phase 2 asset and supportive data have historically commanded valuations in the high hundreds of millions to low billions of dollars when the mechanism is novel and the unmet need is clear. If CNR-401 reaches a positive Phase 1 readout and the platform begins generating licensing revenue, Canurta could be worth a meaningful multiple of its current disclosed capital base (scenario, not a forecast). The downside-protected version of the same story is that the Canurta Naturals extraction asset has standalone value as a cGMP botanical contract manufacturer regardless of the drug pipeline outcome, which is an unusual feature for a seed-stage biotech.

Data Accuracy: YELLOW -- Scenarios constructed from cited milestones; valuation framing is illustrative and explicitly labelled as scenario rather than forecast.

Sources

PUBLIC

  1. [Canurta] Next Generation Botanical Drugs for Complex Diseases | https://www.canurta.com/

  2. [Canurta] About Us | https://www.canurta.com/about-us

  3. [Canurta] Next-Generation Botanical Pipeline | https://www.canurta.com/pipeline

  4. [Canurta] Technology | https://www.canurta.com/platform

  5. [Canurta] Investor Summary | https://www.canurta.com/investor-summary-1

  6. [Canurta] Canurta Naturals to Lead Operational Transition at FSOil Facility | https://www.canurta.com/post/canurta-naturals-to-lead-operational-transition-at-fsoil-facility-expanding-cgmp-botanical-extracti

  7. [Black Dollar Magazine] Canurta founder and CEO Akeem Gardner wants to bring a hemp processing facility to southern Ontario | https://www.blackdollarmag.com/canurta-founder-akeem-gardner-discovering/

  8. [LinkedIn] Canurta Therapeutics company page | https://ca.linkedin.com/company/canurta

  9. [LinkedIn] Akeem Gardner profile | https://www.linkedin.com/in/akeemgardner/

  10. [Ontario Centre of Innovation] Canurta: Exploring the anti-inflammatory benefits of hemp with CEO Akeem Gardner | https://www.oc-innovation.ca/success-stories/canurta-exploring-the-anti-inflammatory-benefits-of-hemp-with-ceo-akeem-gardner/

  11. [PitchBook] Canurta Therapeutics 2025 Company Profile | https://pitchbook.com/profiles/company/503587-81

  12. [Crunchbase] Canurta Therapeutics company profile | https://www.crunchbase.com/organization/canurta-therapeutics

  13. [Crunchbase] Akeem Gardner person profile | https://www.crunchbase.com/person/akeem-gardner

  14. [Tracxn] Canurta 2025 Company Profile & Funding | https://tracxn.com/d/companies/canurta/__1qXf-MdPAzG-_R6cotcJP_GN7g2XliTS7933r5elhUY

  15. [CanadianSME Small Business Magazine] Akeem Gardner on Breaking Barriers in Biotech & Bitcoin | https://canadiansme.ca/akeem-gardner-on-breaking-barriers-in-biotech-bitcoin/

  16. [Newsfile Corp, 2026] Coverage of Canurta funding and patent estate (referenced in research)

  17. [GlobeNewswire, 2026] Life Sciences Investor Forum presentation listing (referenced in research)

  18. [Applied Pharmaceutical Innovation] Partnership with Dr. Neal M. Davies, University of Alberta (referenced in research)

Articles about Canurta Therapeutics

View on Startuply.vc